Real-world outcomes among patients with HER2+ metastatic breast cancer with brain metastases.
DeBusk K, Ike C, Lindegger N, Schwartz N, Surinach A, Liu Y, Forero-Torres A.
DeBusk K, et al. Among authors: surinach a.
J Manag Care Spec Pharm. 2022 Jun;28(6):657-666. doi: 10.18553/jmcp.2022.28.6.657.
J Manag Care Spec Pharm. 2022.
PMID: 35621719
Free PMC article.
Median OS was 22.3 and 37.3 months for patients with and without BMs at baseline, respectively. Patients with BMs had a higher risk of death compared with patients without BMs (HR, 3.2; 95% CI = 2.6-3.8). ...Kendra DeBusk is an employee of Seagen Inc. and owns stock in Sea …
Median OS was 22.3 and 37.3 months for patients with and without BMs at baseline, respectively. Patients with BMs had a higher risk o …